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Abstract
Medical gases are pharmaceutical molecules which offer solutions to a wide array of medical needs. This can range
from use in burn and stroke victims to hypoxia therapy in children. More specifically however, gases such as
oxygen, helium, xenon, and hydrogen have recently come under increased exploration for their potential
theraputic use with various brain disease states including hypoxia-ischemia, cerebral hemorrhages, and traumatic
brain injuries. As a result, this article will review the various advances in medical gas research and discuss the
potential therapeutic applications and mechanisms with regards to the field of neurobiology.
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Introduction
Medical gases, pharmaceutical molecules which offer solu-
tions to a wide array of medical needs, range from tradi-
tional gases (oxygen and nitrous oxide) to gases like nitric
oxide, carbon monoxide, and hydrogen sulfide–all of
which have been recently shown to behave as biological
messenger molecules [1]. Some gases, such as helium and
xenon, have even been shown to be neuroprotective fol-
lowing various brain injuries such as acute ischemic
stroke, perinatal hypoxia-ischemia, traumatic brain injury,
and cardiopulmonary bypass-induced neurologic and neu-
rocognitive dysfunctions [2-4]. In this paper, we will briefly
introduce and review the history of oxygen, helium, xenon,
and hydrogen gas, and discuss the various therapeutic
mechanisms that have been proposed in the current
literature.
Oxygen
Air is composed of 78% nitrogen, 21% oxygen, and less
than 1% of other gases. If more oxygen is needed, hyper-
oxia can be induced to increase the fraction of inhaled
oxygen, and therefore the diffusion of oxygen through
blood. This can be achieved under normobaric, or hyper-
baric conditions. Normobaric hyperoxia (normobaric
oxygen, NBO) is applied via a wide variety of masks that
allow delivery of inspired oxygen ranging from 24% to
90%. Higher concentrations can be delivered via masks
with reservoirs, tightly fitting continuous positive airway
pressure-type masks, or through mechanical ventilation.
In contrast, under hyperbaric conditions, one can breathe
100% oxygen (small chamber for single occupant), or
breathe compressed air and 100% oxygen intermittently
through a mask or hood (large multiplace hyperbaric
chamber).
Mechanism underlying the theraputic effects of hyperoxia
Hyperoxia is an attractive therapeutic option because it
has several properties of an ‘ideal’ protective agent.
Unlike most pharmaceutical drugs, oxygen is simple to
administer, easily diffuses to target tissues, is well toler-
ated, can be delivered in 100% concentrations without
significant side effects, and can theoretically be combined
with other treatments.
To date, the mechanisms underlying the therapeutic
effects of hyperoxia are quite complex, with a variety of
mechanisms under investigation (Figure 1). According
to some studies, hyperoxia has been shown to modulate
aerobic metabolism, and to regulate blood flow via
vasoreactivity. At the same time, the changes in aerobic
metabolism can also regulate blood flow in the body.
Therefore, although described independently, the
mechanisms underlying the therapeutic potential of
hyperoxia are vast and influence each other, to a certain
degree. * Correspondence: johnzhang3910@yahoo.com
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Delivery of oxygen to tissues depends on adequate ven-
tilation, gas exchange, circulatory distribution, and the
partial pressure of inhaled oxygen. At normal sea levels,
the partial pressure of oxygen (pO2) of inspired air is
around 160 mmHg. This progressively drops as oxygen
is carried further in the body. In other words, the first
drop occurs in the lungs because of water vapor and dif-
fusion, then in the vasculature leaving the alveolar capil-
laries, where the pO2 is around 104 mmHg, as it moves
towards organs and tissues for perfusion. The diffusion
distance of oxygen in a tissue is approximately 100~200
μm and an oxygen partial pressure of almost zero has
been reported at about 100 μm from blood vessels [5,6].
It is also important to recall that the hemoglobin dis-
sociation curve shows hemoglobin to be 100% saturated
when the partial pressure of arterial oxygen (PaO2)i s
approximately 80 mmHg. Under conditions of complete
saturation, as is the case with 100% oxygen administra-
tion under normobaric conditions, each gram of healthy
hemoglobin contains 1.39 ml of oxygen, which accounts
for only a small increase in the oxygen content of arter-
ial blood.
Additionally, the amount of oxygen physically dissolved
in the blood also increases proportionally with the partial
pressure of ambient oxygen. The amount of oxygen dis-
solved in plasma is negligible under physiological oxygen
tensions, but normobaric hyperoxia may increase the
amount of dissolved oxygen by approximately 0.5~1%
while hyperbaric oxygen can increase it considerably
more. Inhalation of 100% oxygen at normal atmospheric
pressure yields a 5-to 7-fold increase in arterial blood oxy-
gen tension, which can only satisfy one-third of the oxygen
requirements of resting tissue due to the low plasma solu-
bility of oxygen. However, under hyperbaric conditions
(such as 3 atmosphere absolute), the arterial blood oxygen
tension may reach values close to 2,000 mm Hg, resulting
in levels of plasma dissolved oxygen (about 6%) that can
meet the average requirements of resting tissues, without
a contribution from oxygen bound to hemoglobin [7].
Figure 1 Mechanisms underlying the protective effects of hyperoxia. The mechanisms underlying the therapeutic effects of hyperoxia are
quite complex, with a variety of mechanisms ranging from stem cell mobilization to enhancement of the neuroplasticity process under
investigation.
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the capillary blood to tissue cells is a key mechanism by
which hyperoxygenation of arterial blood can improve
effective cellular oxygenation, even at a low rate of tis-
sue perfusion. The increased oxygen supply during nor-
mobaric hyperoxia or hyperbaric hyperoxia contributes
to bactericidal effects within the tissue. Anaerobic
microorganisms, in particular, do not have defense
mechanisms against the increased production of reactive
oxygen species (ROS) in hyperoxic environments [8,9].
Hyperoxia on the hemodynamics
In healthy animals and humans, oxygen inhalation can
increase the total peripheral vascular resistance, second-
ary to systemic peripheral vasoconstriction. This results
in a temporary increase in blood pressure, which is
rapidly counterbalanced by a decrease in heart rate and
cardiac output [10].
The brain has an extremely high metabolic rate; its
oxygen demand exceeds that of all organs except the
heart. Despite its relative small size (2% of total body
weight), the brain receives approximately 20% of the
cardiac output, and accounts for about 20% of the
body’s oxygen consumption. Over a normal physiologi-
cal range of PaO2 (7 ± 13.33 kPa), there is little change
in cerebral blood flow (CBF). Changes in oxygen tension
are a potent stimulus for arterial dilatation/contraction.
Rodent [11] and human [12] studies have shown that
hyperoxia induces beneficial hemodynamic effects.
Kety and Schmidt originally described a reduction of
13% in CBF, and a moderate increase in the cerebrovas-
cular resistance of young male volunteers inhaling 85-
100% oxygen [13]. Omae and colleagues confirmed that
increases in PaO2 led to a significant reduction in the
flow velocity within the middle cerebral artery. However,
when oxygen was increased from 100% at 1 ATA to
100% oxygen at 2 ATA, there were no further reduc-
tions in flow velocity within the middle cerebral artery
[14].
Additionally, the increase in the mean partial pressure
of oxygen in the tissues by hyperoxia has significant het-
erogeneities. The increase in heterogeneity is speculated
to be a result of the redistribution of blood flow, with
vasoconstriction in some areas and shunting in others.
Under pathological conditions, hyperoxia may lead to the
opening of collaterals, or a ‘reverse steal’ effect through
diversion of blood from non-injured tissues into injured
tissues. The unique combination of hyperoxia-induced
vasoconstriction and high arterial blood oxygen decreases
the vasogenic component of increased tissue hydrostatic
pressure while preserving a high blood-to-tissue oxygen
partial pressure gradient.
In the past, various mediators and mechanisms, such
as increased effects of serotonin, nitric oxide synthase
inhibition, inhibition of endothelial prostaglandin
synthesis and increased leukotriene production, have
been shown to play a key role in cerebral oxygen vasor-
eactivity [15].
Hyperoxia on energy metabolism
The downstream molecular effects of improved oxyge-
nation are largely hypothetical. Increased aerobic meta-
bolism leads to an increased production of ATP during
aerobic cellular respiration in the mitochondria.
This hypothesis is indirectly supported by measure-
ments of lactate and pyruvate in the cerebrospinal fluid
(CSF). Daugherty et al investigated the oxygen consump-
tion and mitochondrial redox potential during oxygen
therapy [16]. Results showed that hyperbaric oxygen
(HBO) not only induced an increase in oxygen consump-
tion in both injured and sham-injured animals, but also
enhanced the recovery of mitochondrial function [16].
R o c k s w o l de ta la l s or e v e a l e dt h a tH B Om a yi m p r o v e
aerobic metabolism by increasing the cerebral metabolic
rate of oxygen and decreasing the lactate levels in CSF
[17]. A more recent study revealed significantly greater
improvements in the cerebral blood flow, cerebral meta-
bolic rate of oxygen, microdialysate lactate, and the lac-
tate/pyruvate (L/P) ratio when the partial pressure of
oxygen in the brain tissue was ≥ 200 mm Hg, which is
achieved during HBO or normobaric oxygen treatment
[18]. Additionally, they found the effect of HBO on treat-
ment to be more robust than that of normobaric oxygen
on oxidative cerebral metabolism [18]. Normobaric
hyperoxia, which increases brain tissue oxygenation, has
a variable effect on the lactate and lactate/pyruvate ratio
in addition to having a preferential metabolic benefit
[ 1 9 ] .B yu s i n ge a r l yh i g hr e s o l u t i o np o s i t r o ne m i s s i o n
tomography, Lou et al showed that exposure of the
ischemic brain to HBO can partially reverse the down-
ward trend for glucose utilization in the ischemic core,
which might explain the reported benefits of early HBO
therapy on permanent cerebral ischemia [20].
Hyperoxia on the inflammatory process
HBO contributes to curtail inflammation through various
anti-inflammatory mechanisms. Following injury, white
blood cells can migrate to the injured site producing
inflammation. This is characterized by upregulation of
adhesion molecules and chemokines, which play impor-
tant roles in inflammatory migration. In this regard,
HBO has been shown to decrease the rolling and adhe-
sion mechanisms of polymorphonuclear leukocytes
(PMNL), mediated by b2 integrin glycoproteins CD11/
CD18, in the microcirculation following injuries [21].
Hyperoxia also reduces the expression of the endothelial
adhesion molecules E-selectin [22] and intracellular
adhesion molecule-1 (ICAM-1) [23]. Additionally, hyper-
oxia induces the production of endothelial NO synthase
(eNOS) which synthesizes nitric oxide (NO), a protein
which contributes to the reduction of PMNL adhesion to
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hyperoxia reduces the mRNA and protein levels of
cyclooxygenase-2 (COX-2), a k e ye n z y m eo fp r o s t a n o i d
metabolism which also has a predominantly negative
effect on inflammation induced by experimental ischemia
[26]. By using directed microarray analysis, Rink et al
showed that supplemental oxygen limited leukocyte
accumulation at the infarct site by attenuation of the
stroke-inducible pro-inflammatory chemokine response
[27].
Hyperoxia on delayed cell death
Previous research suggests that hyperoxia can inhibit
apoptosis. In several studies, HBO-treated rodents had
reduced apoptotic markers in neonatal hypoxia-ische-
mia, as well as focal and global cerebral ischemia models
[28,29]. Additionally, Henninger et al [30] reported that
normobaric oxygen treatment reduces apoptotic cell
death in the ischemic hemisphere.
Hyperoxia on vascular permeability
Hyperoxia has also been shown to preserve the integrity
of the blood-brain barrier (BBB) by reducing vascular
permeability. Previous studies have shown that early
intra-ischemic HBO treatment reduces the BBB disrup-
tion, hemorrhagic transformation, and subsequent mor-
tality following focal cerebral ischemia [31,32].
Additionally, Sun et al used MRI to demonstrate that
hyperbaric and normboaric oxygen treatments signifi-
cantly reduce post-ischemic BBB permeability on post-
contrast T1-weighted images in middle cerebral artery
occlusion (MCAO) models [33].
Protection of the BBB by hyperoxia may be related to
the reduction of matrix metalloproteinases (MMPs),
which are predominant enzymes involved in the degra-
dation of the components of the vascular basement
membrane [34]. This effect may be mediated by
NADPH oxidase [35] and/or hypoxia-inducible factor
(HIF) [36] because reduction of NADPH oxidase after
hyperoxia results in the decreased production of ROS,
which play an important role in the activation of MMPs
[37]. Moreover, HIF-1 has been implicated in the con-
trol of MMPs, including MMP-2 (gelatinase A) and
MMP-9 (gelatinase B), which can degrade components
of the extracellular matrix surrounding cerebral blood
vessels [38].
Hyperoxia on the plasticity process
Following an initial cerebral injury, post-acute brain plasti-
city is critical for determination of functional brain
improvement. The absence of neuroanatomical plasticity
following cerebral injury is attributable to several factors,
including glial scars, lack of neurotrophins, and growth
inhibitory molecules. Neurite outgrowth inhibitor (Nogo-
A), one of the most powerful growth inhibitors, is related
to the plasticity of the central nervous system. Zhou et al
revealed that HBO significantly decreased the levels of
Nogo-A, and Ras homolog gene family, member A (RhoA)
during an ischemic injury in the cortex, which might
partially contribute to the improvement of neurological
function [39]. Garcia et al also showed that a transient
acute hyperoxia stimulus, whether caused by breathing
HBO or reoxygenation following hypoxia, is a powerful
stimulant for orthodromic activity and neural plasticity in
the CA1 hippocampus [40]. Additionally, hyperbaric oxy-
gen treatment promotes neural plasticity by increasing
Map-2 expression and decreaseing GFAP [41].
Neuroclinical application of oxygen therapy
Oxygen therapy remains a cornerstone of modern medi-
cal practice and many of its physiological actions have
already been elucidated. With regards to the field of
neurology, oxygen therapy has been studied in stroke
and traumatic brain injury (TBI) cases due to the preva-
lence of both diseases.
Normobaric hyperoxia on traumatic brain injury
In 1998, Thiagarajan et al applied hyperoxia in TBI
patients undergoing hyperventilation. Their results
showed that increases in the PaO2 above normal levels
could offset the deleterious effects of hyperventilation on
jugular bulb oxygen saturation and arteriovenous oxyge-
nation content difference in patients with head injuries
[42]. To this date, the most cited study was conducted by
Tolias et al [43]. This was a prospective study where 52
patients with severe TBI were treated with a FiO2 (frac-
tion of inspired oxygen) of 100% for 24 h within 6 h of
admission. When compared with 112 patients in a histor-
ical cohort study, patients treated with 100% FiO2 had
increased glucose levels and decreased glutamate and lac-
tate levels. Microdialysis also showed reductions in the
lactate/glucose and lactate/pyruvate ratios. Additionally,
intracranial pressure was reduced significantly in the
treatment group, while there were no changes in cerebral
perfusion pressure. Unfortunately, one of the limitations
of this study was the potential for hyperoxia-induced pul-
monary toxicity due to the longevity of the treatment.
Magnoni et al performed a variation of the Tolias study
by administering 100% FiO2 to patients with TBI for 3 h
[44]. Interestingly, similar results were found except that
the lactate/pyruvate ratio, and the levels of glucose and
glutamate remained unchanged.
In a study by Nortje et al, oxygen-15 positron emission
tomography (15O-PET) analysis revealed that normoba-
ric hyperoxia administered following TBI conferred a
preferential metabolic advantage to the “at risk” peri-
lesional tissue, as measured by improved local cerebral
metabolic rate of O2 (CMRO2) and brain tissue oxygen
tension (PbtO2)[ 1 9 ] .H o w e v e r ,as t u d yf r o mD i r i n g e re t
al showed that 1 h hyperoxic treatment was not sufficient
to exert positive effects on cerebral O2 metabolism [45].
Cumulative analysis of these studies delineates the bene-
ficial effects of normobaric hyperoxia on TBI. In fact,
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invasive, and easily applicable adjunct in the early man-
agement of TBI.
Normobaric hyperoxia on stroke
Several groups have become interested in NBO because
it offers distinct advantages over HBO: it is widely avail-
able, simple to administer, inexpensive and most impor-
tantly, can be started very quickly by paramedics after
stroke onset.
Recent rodent studies using the transient middle cere-
bral artery ischemia-reperfusion model have shown that
NBO improves pathological, neurobehavioural, and neu-
roimaging outcomes following stroke. Singhal et al
showed that NBO therapy administered during ischemia
and during the immediate post-reperfusion period results
in a 70% reduction of hemispheric infarct volumes in rats
[11,46]. The therapeutic time window for NBO in
rodents is short (approximately 30~45 min); Singhal et al
used serial diffusion-weighted imaging (DWI) to show
that initiating treatment at earlier time points enhances
the degree of neuroprotection and attenuates the severity
and the volume of ischemic injury.
The first study on normobaric hyperoxia in stroke was
an observational study led by Ronning and Guldvog. Their
results showed that the one-year survival was higher in
room-air treated control patients with mild-moderate
stroke when compared to those treated with 3 L/min nasal
oxygen [47]. However, there were a lot of shortcomings in
this study. For example, the time to treatment was rela-
tively late as 18% patients did not receive the assigned
‘therapy’, 12.7% had hemorrhagic stroke.
The first therapeutic trial of NBO (45 L/min oxygen via
a facemask) was carried out by Singhal et al [12]. Results
showed that NBO-treated stroke patients had improved
National Institutes of Health Stroke Scale (NIHSS) scores,
reduced growth of DWI lesion volumes, and an increase
i nt h ev o l u m eo f‘penumbral’ tissue. NBO therapy also
resulted in a marked improvement in the visibilty of DWI
lesions. Additionally, the percentage of MRI voxels
improving from baseline “ischemic” to 4-h “non-ischemic”
values tended to be higher in NBO-treated patients. Cere-
bral blood volume and blood flow within ischemic regions
also improved with hyperoxia. These findings show that
initation of NBO treatment within 12 h of stroke transi-
ently improves clinical features as well as MRI parameters
of ischemia.
Building on their previous work, Singhal et al. performed
multivoxel magnetic resonance spectroscopic imaging and
diffusion/perfusion MRI in stroke patients exposed to nor-
mobaric hyperoxia (45 L/min oxygen through a face mask
for 8 h), or room air. Imaging, performed before, during,
and after therapy, helped conclude that normobaric hyper-
oxia improves aerobic metabolism [48]. Additionally, a
similar study showed that administration of 40% FIO2 (via
venture masks) to patients with middle cerebral artery
strokes decreased stroke-related complications as well as
mortality [49]. However, these studies need to be further
validated due to their small sample size.
Hyperbaric oxygen on traumatic brain injury
Hyperbaric oxygen treatments typically involve pressuri-
zations between 1.5 and 3.0 ATA for 60 to 120 min daily.
A number of studies have demonstrated the effectiveness
of HBO in the treatment of TBI using the Glasgow Coma
Scale (GCS) and Glasgow Outcome Scale (GOS) to eval-
uate outcomes. These studies have demonstrated that
hyperbaric oxygen treatment increases GCS and GOS
scores [50-53]. Additionally, Rockswold et al showed that
HBO therapy could also increase cerebral metabolic rate
of oxygen (CMRO2) and decrease lactate levels in the
CSF, thereby improving aerobic metabolism in patients
with severe brain injuries [16,17].
Shi et al used single photon emissions computed tomo-
graphy (SPECT) images and computed tomography scans
(CT) to evaluate the use of HBO therapy on neuropsy-
chiatric disorders following TBI. The results, which
revealed that hyperbaric oxygen treatment improved
regional cerebral blood flow, were consistent with
another study conducted by by Sukoff et al in 1982 [54].
With regards to CSF pressures, Mogami et al. found
that CSF pressures of severely brain-injured patients
decreased during the beginning of treatment, stayed at a
low level during treatment, and rebounded post-treat-
ment [55]. These findings are similar to what Hayakawa
et al found a few years later [56].
Although much there have been studies on the effi-
cacy of HBO therapy following TBI, there is insufficient
evidence to prove or disprove HBO’s therapeutic effec-
tiveness. The evidence indicates that there is a small
chance of a mortality benefit with HBO therapy in TBI
patients, depending on the subgroup selection. HBO’s
effect on functional status as well as the incidence and
clinical significance of its adverse effects are unclear. In
four reviews, the authors consistently concluded that the
routine adjunctive use of HBO therapy in patients with
TBI cannot be justified due to various limitations in the
existing studies, such as a small number of studies,
modest numbers of patients, and the methodological
and reporting inadequacies of the primary studies
[57-60].
Hyperbaric oxygen on ischemic stroke
In 1960, Boerema et al showed, for the very first time,
that exsanguinated pigs could survive by placing them in
a HBO chamber [61]. This study intensified efforts to use
HBO to treat organ ischemia. Unfortunately, 3 years
later, Jacobson and Lawson reported no benefit following
HBO at 2.0 ATA following MCAO in dogs [62]. But
since the 1960’s, numerous animal studies and clinical
trials have documented substantial benefits with HBO in
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focal stroke.
Typical HBO therapy regimens use 100% oxygen at
1.5~2.5 atm pressures for 30~90 min with the time
between sessions and the number of sessions varying
widely. Recent animal data indicates that oxygen therapy
is most effective if applied early, for short durations, and
that long-term benefit can be maximized if the tissue is
reperfused [63-66]. Delayed and repetitive HBO treat-
ments can expand the therapeutic window in rats with
focal cerebral ischemia [67] and can promote neurologi-
cal recovery in the acute setting, while reducing the fre-
quency of recurrent strokes [68-71].
To this date, three randomized clinical trials using
HBO therapy in stroke have been published [72-74], and
all three trials have reported negative results. The first
trial by Anderson et al was interrupted early due to con-
cerns regarding randomization. Interestingly enough,
prior to its discontinuation, the interim analysis revealed
a trend towards improvement in neurological examina-
tion and infarct volumes in the HBO therapy patient
group. In the second trial, conducted by Nighoghossian
et al, the Rankin score, Trouillas score, and the Orgogozo
scale score, were used to evaluate the effectivess of HBO
therapy. The results showed that Orgogozo and Trouillas
scores at 1 year were significantly better in the HBO
group; however, a comparison of the pre-and post-ther-
apy differences between the HBO groups at 6 months
and 1 year did not show statistical significance on any of
the scoring systems. In the final clinical study, conducted
by Rusyniak et al, the results after 3 months revealed that
the neurological outcome scores (NIHSS, Rankin scale,
Barthel index and Glasgow outcome scale) were signifi-
cantly better in the sham group (100% oxygen) compared
to the HBO-treated group in all scales except the Barthel
index. These clinical studies suggested that HBO therapy
does not benefit to ischemic patients and may even be
harmful in stroke.
Following these three clinical trials, Bennett et al con-
ducted a meta-analysis and review of the trials, and sug-
gested that existing data do not justify the use of HBO
therapy in stroke patients, and that the lack of a signifi-
cant effect may be related to the small number of
patients, delays in initiating HBO therapy, and absence
of successful blinding [75].
Hyperoxia Pre-Conditioning
Pre-conditioning is a process by which an organism’s
exposure to a stress/stimulus allows it be more resilient
against the same stimulus during future encounters. One
of the first studies, led by Dahl et al, found that rats pre-
conditioned with a brief episode of anoxia could survive
longer (90 sec) than control animals (60 sec) following a
prolonged exposure to anoxia [76]. In this study, they
speculated that energy metabolism played an important
role in the prolonged survival time of the preconditioned
rats. This effect was later confirmed in adult brain slices
with pre-exposure to a short (5 min) anoxic episode [77].
That same year, Geft et al introduced brief periodic cor-
onary occlusions up to 18 times by inflating and deflating
the balloon for periods of 15, 10, or 5 min, followed by
15-min periods of reperfusion. Their findings suggested
that intermittent reperfusion had a beneficial effect and
may prevent necrosis, even when total occlusion time
exceeds 200 min [78]. It wasn’t until 1986 that Murry et
al proposed the concept of pre-conditioning, and con-
firmed the protective effects of ischemia pre-conditioning
on myocardial ischemia [79]. A turning point came when
Kitagawa et al documented the ability of brief bilateral
carotid occlusion to protect gerbil hippocampal CA1 pyr-
amidal neurons against prolonged global ischemia; these
authors coined the term ‘ischemic tolerance’ to describe
the phenomenon [80]. To this date, the protective effects
of ischemic pre-conditioning have been confirmed fol-
lowing ischemic exposures to the heart [81], brain [82],
lung [83], kidney [84], and liver [85].
Compared with hypoxic pre-conditioning, hyperoxia
pre-conditioning via HBO or NBO pre-conditioning
seems to be a safer and more readily available in clinical
practice. In 1986, Martin et al found pre-treatment with
endotoxin and pre-conditioning with hyperoxia could
reduce the inflammatory response in paraquat-induced
neutrophil alveolitis [86]. Four years later, D’Brot et al sug-
gested that prior exposure to alveolar hyperoxia could pre-
vent the hypoxia-induced enhancement of bronchial
reactivity to carbachol and histamine, which involves a
cyclooxygenase-dependent mechanism [87]. In 1996, a
Japanese group showed that repeated exposures to hyper-
baric oxygen (100% oxygen at 2ATA for 1 h each) could
increase the tolerance of the brain against ischemic neuro-
nal damage, in which the induction of HSP-72 synthesis
plays an important role [88]. Since then, the protective
effects of hyperoxia pre-conditioning, especially the hyper-
baric oxygen pre-conditioning, have been investigated in a
lot of animal models.
Mechanisms underlying the protective effects of hyperoxia
pre-conditioning
Previous studies have suggested that the protective
effects of hyperbaric oxygen pre-conditioning could be
attributed heat shock proteins (HSPs) [88,89]. However,
Vince et al recently suggested that the benefits of HBO
pre-conditioning may not be due to inducement of HSP
expression in circulating blood cells, but might involve
an enhancement of the stress response [90] (Figure 2).
Exposure to hyperbaric oxygen can generate oxidative
stress [91], which can subsequently activate antioxidants
that could confer protective effects. Although excessive
oxidative stress can damage tissues, previous works have
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produce an increased antioxidant response [92-98].
Additionally, intermittent exposures to hyperoxia may
produce a temporary ‘hypoxic environment’ between two
hyperoxia exposures which may induce the expression
and/or activity of a key oxygen sensor known as hypoxia-
inducible factor-1 (HIF1) [99,100]. The increased HIF1
level may regulate the expressions of its downstream
genes including vascular endothelial growth factor (VEGF)
[101], COX-2 [102,103], erythropoietin (EPO) [100], nitric
oxide synthase (NOS) [104] and MMP [105]. Moreover,
hyperoxia pre-conditioning can suppress the activity of
p38 mitogen activated protein kinase (MAPK) [106-108]
and induce expression of brain-derived neurotrophic fac-
tors [106], which can also induce the expression of HIF-1
[109].
Other important mechanisms of protection from hyper-
oxia pre-conditioning include a reduction in apoptosis,
especially following ischemic brain injury [106,110-112].
Within the past decade, researchers have also investigated
the role of transporters and key inflammatory cytokines,
such as glutamate transporters, tumor necrosis factor-a,
nuclear factor-B, ribosomal protein S6 kinases, and mito-
chondrial ATP-sensitive potassium, in the protective
effects of hyperoxia pre-conditioning [89,113-116]. Some
have even shown that the genes/proteins relevant to neu-
rotrophin and the inflammatory-immune system may be
involved in HBO-induced protection [117].
Application of hyperoxia pre-conditioning
The neuroprotective effects of hyperoxia have been
investigated in various models, including global ischemia
[105], forebrain ischemia [107], surgical brain injury
[102], ischemia-reperfusion injury [97,110], neonatal
hypoxia-ischemia [111], intracerebral hemorrhage [89],
and spinal cord ischemia [118].
Oxygen toxicity
Oxygen toxicity is a legitimate concern with regards to
the clinical application of hyperbaric oxygen. Once oxy-
gen is applied at a relatively high pressure for prolonged
periods of time, various systems and organs can be nega-
tively affected including the central nervous and pulmon-
ary systems [119]. In clinical practice, oxygen is usually
applied at 2~3 ATA and the duration of oxygen treat-
ment ranges from 60 min to 2 h. Moreover, the oxygen
inhalation is frequently interrupted by inhalation of air at
corresponding pressures. Under these conditions, oxygen
toxicity is rare. However, in certain environments, oxygen
may be applied at high pressures and for longer durations
such as in the treatment of central nervous system
decompression sickness/dysbarism [120] and with pre-
emies [121]. Under this condition, the oxygen partial
pressure and treatment duration should be closely moni-
tored to minimize the potential for the oxygen toxicity.
Although some attempts to minimize the detrimental
effects of oxygen exposure with anti-oxidants have been
made, nothing has been confirmed [122].
Helium
Introduction
In addition to being a well-defined noble gas, helium is
the second most abundant element in the universe, and
accounts for 24% of the elemental mass of our galaxy.
Helium has many applications in cryogenics, the cooling
of superconducting magnets, MRI scanners, arc welding,
and can also be used as a gas pressureizer. Helium has
traditionally been used to help decrease the incidence of
decompression sickness during deep sea diving [123,124].
In 1934, Barach proposed the use of helium as a new
therapeutic gas [125], and subsequently proposed heliox
(helium/oxygen gas mixture) as a potential therapy for
Figure 2 Mechanisms Underlying Hyperoxia Pre-conditioning. The protective effects of hyperoxia pre-conditioning can be attributed to a
variety of mechanisms ranging from VEGF activaition to anti-oxidant production.
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increasingly demonstrated the benefits of heliox inhala-
tional therapy. Within the past decade, heliox has
become a focus of renewed interest as treatment for
acute asthma exacerbations [127], bronchiolitis [128],
chronic obstructive pulmonary disease (COPD) [129].
Heliox has also been recognized as an important adjunct
in the treatment of severe asthma exacerbations in the
2007 guidelines published by the National Heart, Lung,
and Blood Institute. During treatment of severe asthma
exacerbations in children, inhalational heliox therapy led
to significant improvements in pulsus paradoxus, peak
flow, and dyspnea [130]. The therapeutic effects of
helium may be attributed to an increased flow rate and
decreased turbulent flow, resulting in deeper penetration
of gases to the distal alveoli, higher minute volumes,
and improved ventilation. Additionally, helium has been
shown to have a high diffusion coefficient for carbon
dioxide relative to oxygen. Correspondingly, this diffu-
sion coefficient may facilitate an environment for
increased pulmonary exhalation of trapped carbon diox-
ide (carbon dioxide washout effect), which is another
important factor underlying the therapeutic effect of
heliox [131].
Despite the first clinical success of heliox use in 1935
and an ample published support over the last decade,
heliox is still not widely available in acute care facilities.
According to many high level researchers and clinicians,
much of the evidence for its use is anecdotal with a pau-
city of level 1 data. Further studies with homogeneous
logistics, a larger patient population, and a more defini-
tive outcome measure are needed to clearly define the
utility of heliox.
Biological effects of helium and potential mechanisms
Helium has been reported to increase the coronary col-
lateral circulation [132] and enhance the vasodilatory
effects of inhaled nitric oxide on pulmonary vessels
[133] (Table 1). In healthy men, heliox improved exer-
cise tolerance while reducing rising lactate levels, with-
o u tas i g n i f i c a n tc h a n g ei nv itals i.e. blood pressure or
heart rate [134]. In 2007, Pagel et al applied three cycles
of 70% He-30% O2 for 5 min interspersed with 5 min of
70% N2-30% O2 before opening up a left anterior des-
cending coronary artery occlusion. Results showed that
pre-conditioning with helium could provide cardiopro-
tection by activating pro-survival signaling kinases and
inhibiting the opening of the mitochondrial permeability
transition pore (mPTP) [135]. In the following year, Hei-
nen et al also applied heliox as a pre-conditioning mod-
ality in a rat heart ischemia/reperfusion model. Their
results revealed that the cardioprotective effects of
heliox pre-conditioning in young rats, which were
mediated by mitochondrial uncoupling and Ca
2+-sensi-
tive potassium channel activation [136]. In a series of
studies led by Pagel et al, researchers found that reactive
oxygen species (including nitric oxide) [137,138], mito-
chondrial adenosine triphosphate-regulated potassium
channels, mitochondrial permeability transition [139],
and opioid receptors [140] played critical roles in
the cardioprotective effects induced by helium pre-
conditioning.
With regards to human clinical trials, Lucchinetti et al
reported no protection with helium use. Specifically, 8
healthy adults were recruited to inhale helium at an end-
tidal concentration of 50% from 15 min before ischemia
to 5 min after the onset of reperfusion. Although their
results indicated that inhaled helium diminishes the post-
ischemic inflammatory reaction, human endothelium was
n o ta m e n a b l et op r o t e c t i o nb yh e l i u ma t5 0 %in vivo
[141].
Application of helium in neurology
Few studies have truly investigated the effects of heliox
treatment or pre-conditioning in the nervous system. In
2007, Pan et al compared the efficacy of hyperoxia
( 1 0 0 %o x y g e n )a n dt h a to fh e l i o x( 3 0 %o x y g e n / 7 0 %
helium) during the ischemia/reperfusion process in the
brain [142]. Their results showed that heliox was super-
ior to hyperoxia with regards to infarct volume reduc-
tions and improvements in neurological deficits at 24 h.
One year later, Coburn et al reported that helium could
exert neuroprotective effects at elevated pressures in an
in vitro model of traumatic brain injury [2]. However,
the exact mechanism underlying the protective effects of
heliox has not been reported.
These results seems to conflict with those in the study
led by Pan et al, where body temperature, mean arterial
blood pressure, heart rate, oxygen saturation and laser
Doppler regional cerebral blood flow parameters were
not significantly different before, during or after MCAO
injury-neither between the control, hyperoxia, nor heliox
groups. In addition, to this date two in vitro studies have
refuted the protective effects of helium. They reported
that heliox was detrimental to neurons [143], and
human tubular kidney cells [144].
Xenon
For decades, volatile anesthetics have been extensively
studied with regards to their potential neuroprotective
properties. A colorless, heavy, odorless noble gas, xenon
has been of particular interest to researchers because of
its possible neuroprotective properties.
Biological effects of xenon and potential mechanisms
Current evidence suggests that xenon induces anesthesia
and exerts its analgesic actions by inhibiting the N-
methyl-D-aspartate (NMDA) receptor signaling pathway
[145,146]. Under conditions that mimic synapses of
mammalian systems, non-NMDA receptors were found
to be insensitive to xenon [147]. Interestingly, xenon
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(kainite) was directly applied to recombinant AMPA
receptors; however, the sensitivity of these receptors to
xenon was negligible when they were activated by the
natural agonist (glutamate), to mimic synaptic conditions
[147].
In addition, xenon can inhibit (a4)2(b2)3 nACh recep-
tors expressed in Xenopus oocytes, whereas the a4b4
nACh receptor was only slightly affected [148]. Xenon
also competitively blocks the 5HT3A receptor, which
has been implicated in regulation of emesis and periph-
eral nociception, at clinically relevant concentrations
[149,150]. Additionally, Xenon also activates TREK
channels [151], which has a neuroprotective role during
spinal chord ischemia (Heurteaux et al., 2004).
In addition to acting on receptors, xenon affects neuro-
transmitter release. In rats, xenon stimulates noradrener-
g i cn e u r o n si nt h eh y p o t h a l a m u sm o r et h a nn i t r o u s
oxide. In vivo microdialysis studies in the rat cerebral
cortex revealed that xenon induced an initial increase in
ACh release followed by a gradual decrease [152], while
there were no xenon-induced effects on acetylcholines-
terases in vitro [153]. Additional studies have demon-
strated that xenon may act on the secondary messenger
signaling pathway via increases in cyclic guanosine
monophosphate (cGMP). Galley et al showed that xenon
can increase cGMP levels in the spinal cord, brainstem,
and hippocampus, without altering the activity of the
neuronal nitric oxide synthase [154]. Furthermore, Pet-
zelt et al showed that xenon can influence mechanisms
regulating the Ca
2+ release channel on plasma mem-
branes [155]. In rat brain synaptic plasma membranes,
xenon inhibits plasma membrane calcium ATPase pump
activity, resulting in an increase in neuronal Ca
2+ concen-
tration and an altered excitability in these cells [156]. The
decrease in regional CBF after xenon treatment [157]
may help reduce intracranial pressure, and the regional
cerebral metabolic rate for glucose [158].
In terms of the cardioprotective effects of xenon, studies
have shown that it can stimulate several important intra-
cellular prosurvival signaling kinases, including protein
kinase C (PKC) [159,160], MAPK [159,161], HSP 27 [161],
extracellular signal-regulated kinases 1/2 [162], Akt, GSK-
3b,a n dC a
2+-induced mPTP [163]. Xenon’sr o l ei na n t i -
apoptotic mechanisms also demonstrates its neuroprotec-
tive qualities [164,165].
Furthermore, studies have suggested that xenon plays
an important role in the anti-inflammatory process.
Xenon has been specifically shown to increase the
removal of P-selectin glycoprotein ligand-1 (PSGL-1) and
L-selectin from the neutrophil surface in vitro.S i n c e
both selectins are involved in the initial contact between
neutrophils and endothelial cells, xenon may affect neu-
trophil adhesion to endothelium during ischemia/reper-
fusion injury [166]. Moreover, xenon has been shown to
prevent TNF-a-induced expression of ICAM-1 and to
decrease TNF-a-induced transcriptional activity of
nuclear factor B( N F - aB). However, xenon’sp r o t e c t i v e
effect is abolished by functional blockade of COX-2 dur-
ing xenon-induced late myocardial pre-conditioning
[167].
Application of xenon in neurology
Since the discovery of xenon as an NMDA receptor
antagonist, there has been growing interest in its poten-
tial use as a neuroprotectant. Some of the features of
xenon that specifically interest scientists and researchers
include its rapid introduction into the brain, favorable
hemodynamic profile with little or no toxicity, and its
inability to be be metabolized [168] (Table 2).
Xenon has been shown to be a remarkably potent neu-
roprotectant in a variety of models [169]. Its dose-depen-
dent neuroprotective effects have been studied in rat
neuronal-glial co-cultured with NMDA-induced toxicity,
glutamate-induced toxicity, hypoxic injury, and oxygen-
glucose deprivation [170-172]. The protective effects of
xenon have also been identified in rodents subjected to
focal ischemia and neonatal hypoxic-ischemic injury
[173,174]. Additionally, at subanesthetic doses, xenon has
been shown to offer global cerebral neuroprotection by
reducing the ischemia-induced neurotransmitter release
as well as subsequent cell injury and neuronal death that
follows an ischemic attack. Maximal neuroprotection was
Table 1 Biological Effects and Potential Mechanisms of Helium
BIOLOGICAL EFFECTS POTENTIAL MECHANISMS
Coronary Collateral Circulation Prosurvival Signaling Kinases [137]
Improve Exercise Tolerance MPTP Opening [139]
Anti-Arrhythmic Effect Mitochondrial Uncoupling [136]
Anti-Tumor Effect Ca
2+-Sensitive Potassium Channel [136])
Anti-Inflammation Reactive Oxygen Species [137,138]
Hypothermia Mitochondrial ATP-Regulated K
+ Channel [139]
High Pressure Nervous Syndrome Mitochondrial Permeability Transition [139]
Neuroprotective Effect Opioid Receptors [140]
Myocardioprotective Effect COX-2 Activity [23]
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xenon was administered up to 4 h after intrastriatal
NMDA injection and up to at least 2 h following the
induction of transient brain ischemia [175].
In one study, Natale et al investigated the neuroprotec-
tive properties of xenon by evaluating its morphological
changes on rat arcuate nucleus. After 3 h, 1, 2, 5, or 7 days
from gas exposure, the neuronal damage was significantly
r e d u c e di nt h ex e n o nt r e a t m e nt group. They concluded
that xenon could be regarded as a promising neuroprotec-
tive agent [176]. In a neonatal hypoxia-ischemia model,
Dingley et al showed that 3 h of xenon administration, fol-
lowing hypoxia-ischemia, provided short-term neuropro-
tection in neonatal rats [174].
Researchers have also explored the possibility of using
xenon in combination with other therapeutic strategies
to evaluate its possible synergistic neuroprotective cap-
abilities. In one study, a combination of xenon and
hypothermia, administered 4 h following hypoxic-
ischemic injury, provided synergistic neuroprotection in
neonatal rats [177]. Studies also revealed that the combi-
nation of xenon and dexamethasone could offer additive
neuroprotection both in vitro and in vivo [178] (Table 2)
Recently, xenon has been investigated as a brain pre-
conditioning agent. Ma et al observed that xenon-
induced pre-treatment in neonatal hypoxic-ischemic rats
decreased infarction size and improved neurological
function [179]. Additional pre-conditioning studies with
Table 2 A Summary of the Neuroprotective Effects of Xenon
Model Intervention Results Reference
NMDA, glutamate, or
oxygen deprivation induced
neuronal injury
Xenon saturated medium for 24 h (in
vitro)
20%, 40%, 60%, 75% xenon (in vivo)
Xenon (60% atm) reduces LDH release to baseline with oxygen
deprivation; xenon (75% atm) reduces LDH release by 80% with
either NMDA-or glutamate-induced injury. In vivo, xenon exerts a
concentration-dependent protective effect and reduces injury by
45% at the highest xenon concentration tested (75% atm).
[170]
Hypoxia damaged cortical
neurons from rat embryos
Xenon saturated medium for 2 h Complete protection against cellular damage and prevention of
hypoxia-induced glutamate release
[171]
Hypoxia damaged PC-12
cells
Xenon saturated medium for up to120
min
Xenon results in complete protection against cellular damage
and prevention of hypoxia-induced dopamine release in which
intracellular Ca
2+-ions evolve.
[172]
MCAO in mice 70%, 35% xenon during occlusion for
60 min
Xenon administration improves both functional and histological
outcome
[173]
Neonatal HI 70%, 50% xenon immediately after
insult for 3 h
Xenon administration commenced after hypoxia-ischemia in
neonatal rats provides short-term neuroprotection
[174]
brain slices from rats (OGD)
MCAO
15-75% xenon bubbled medium
50% xenon 2~3 h after MCAO
Xenon, administered at subanesthetic doses, offers global
neuroprotection from reduction of neurotransmitter release
induced by ischemia, reduces subsequent cell injury and
neuronal death
[175]
NMA induced neuronal
damage
70% xenon for 10 min at 3 h, 1, 2, 5, or
7 days before insult
Xenon alone does not induce changes, but reduces about 50%
NMDA-induced cell loss as well as degenerating neurons, with
the maximal neuroprotection at 7 days.
[176]
anesthetic-induced neuronal
apoptosis in vivo and in
vitro
75%, 60%, 30% xenon for 6 h Xenon attenuates isoflurane-induced apoptosis. [164]
nitrous oxide and isoflurane
induced damage
70% xenon for 2 h Xenon pre-treatment prevents nitrous oxide-and isoflurane-
induced neuroapoptosis (in vivo and in vitro) and cognitive
deterioration (in vivo)
[165]
OGD induced damage to
neurons from neonatal mice
75% xenon + Dex (0.001~10 μM) for 6
h
Combination of Xenon and Dex offers neuroprotection
additively in vitro and synergistically in vivo
[178]
neonatal HI 20-70% xenon for 90 min during
hypoxia or 2, 24 h after hypoxia +
hypothermia (30-37°C)
Xenon and hypothermia administered 4 h after hypoxic-
ischemic injury in neonatal rats provides synergistic
neuroprotection
[177]
OGD induced damage to
neurons; neonatal HI
25~75% xenon for 120 min (in vitro);
70% xenon for 120 min (in vivo)
Prosurvival proteins Bcl-2 and brain-derived neurotrophic factor
are upregulated by xenon treatment
[179]
OGD induced damage to
neurons; neonatal HI
12.5~75% xenon for 2 h (in vitro); 20%,
75% for 2 h (in vivo)
Pre-conditioning with xenon and the combination of xenon and
sevoflurane results in long-term functional neuroprotection
associated with enhanced phosphorylated cyclic adenosine
monophosphate response element binding protein signaling
[180]
MCAO in mice 70% xenon for 2 h Xenon pre-conditioning improves histological and neurological
functional outcome in both genders in a stroke model of mice
in which HIF-1a and phosphoAkt evolve
[207]
OGD induced damage to
neurons
75% xenon for 2 h Xenon pre-conditioning clearly involves the activation of KATP
channels.
[208]
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resulted in long-term functional neuroprotection asso-
ciated with enhanced phosphorylated cyclic adenosine
monophosphate response element binding protein sig-
naling [180]. Xenon pre-treatment prevented nitrous
oxide-and isoflurane-induced neuroapoptosis (in vivo
and in vitro) and cognitive deterioration (in vivo) [165].
Hydrogen
The first element in the periodic table is hydrogen (H2).
As the lightest and most abundant chemical element,
hydrogen constitutes roughly 75% of the Universe’s che-
mical elemental mass. In comparison, free hydrogen is
rare on Earth, constituting less than 1 part per million
in the atmosphere, with the majority found in water and
organic compounds.
Hydrogen is continuously synthesized in human cells
during fermentation of non-digestible carbohydrates by
intestinal bacteriain the large intestine, and is later
excreted as flatus [181,182]. This is the basis for the rou-
tinely-used breath hydrogen as a test for gastrointestinal
transit. An estimated 14% to 20% of the total colonic H2
production was reported to be carried through the
human bloodstream and subsequently released into the
lungs [183]. Therefore, exhalation of hydrogen forms the
basis for assessing gastrointestinal motility and transit
time as well as the overgrowth of of small intestinal bac-
terial [184-186].
In 1975, Dole et al first applied hyperbaric hydrogen
when treating mice with squamous cell carcinoma [187].
Since their results revealed significant regression of
tumors, they speculated that hyperbaric hydrogen ther-
apy may act as a free radical decay catalyzer and prove
efficacious in other cancer types [187]. On the other
hand, Kayar et al showed hydrogen gas is not oxidized by
mammalian tissues under hyperbaric conditions and
instead attributed its effect to other unknown properties
[188]. It wasn’t until 2001 that Gharib et al investigated
the anti-inflammatory properties of hydrogen in a schis-
tosomiasis-associated chronic liver inflammation model.
The results revealed that hyperbaric hydrogen at 0.7 MPa
for 2 weeks had significant protective effects on liver
injury by decreasing fibrosis while improving hemody-
namics and the activity of antioxidant enzymes [189].
However, few studies emphasized the therapeutic effects
of hydrogen before 2007. This was when a Japanese
group conducted a series of experiments investigating the
biological effects and therapeutic potency of hydrogen
(~4%) [190]. Since then, a large number of studies have
explored the therapeutic effects of hydrogen in different
tissues including the brain, heart, kidney, lung, and liver.
Mechanisms underlying the bioeffects of hydrogen
One of hydrogen’s antioxidant capabilities is as a free
radical scavenger. It selectively reduces the levels of
hydroxyl radicals (·OH), which are mainly generated
through the Fenton reaction and peroxynitrite (ONOO
-)
in vitro [190], and are both strong oxidants that react
indiscriminately with nucleic acids, lipids, and proteins
to cause DNA fragmentation, lipid peroxidation, and
protein inactivation. Another possible mechanism
underlying the cellular protection afforded by hydrogen
may be its ability to increase antioxidant enzymes such
as catalase, superoxide dismutase, and heme oxygenase-
1 [191,192]. Some studies have suggested that hydrogen
may have antiapoptotic properties, and can inhibit
caspace-3 activation [193].
Therefore, hydrogen has several potential advantages
over current pharmacological due to its safety and ther-
apeutic potency. Hydrogen’s ability to easily traverse the
brain-blood barrier allows it to be safely administered to
human patients. Furthermore, it is capable of rapidly
diffusing through membrane compartments to gain
ready access to the cytosol, mitochondria, and nucleus.
Finally, hydrogen reduces detrimental hydroxyl radicals
and peroxynitrite, but does not compromise essential
homeostatic mechanisms dependent on ROS.
Application of hydrogen in neurology
The potential benefits of hydrogen gas on various brain
pathologies have been investigated since 2007, when the
first hydrogen paper was published (Table 3). In China
[194,195] researchers found that inhalation of 2% hydro-
gen and injection of hydrogen-saturated saline following
hypoxic-ischemic brain injuries evoked neuroprotection
via inhibition of neuronal apoptosis and reduction of cas-
pase-3 and caspase-12 activities. These short-term effects
also translated into long-term improvements in when neu-
robehavioral functions were tested 5 weeks following the
injury [195]. However, Matchett et al reported conflicting
results [196] in moderate and severe neonatal brain
hypoxia (HI) models. In their study, inhalation of 2.9%
hydrogen did not decrease the infarction volume and
brain lipid peroxidation, but there was a trend suggesting
a beneficial effect on middle cerebral artery occlusion in
adult rats. These discrepancies might be attributed to dif-
fering experimental conditions (different degrees of HI
insult, age of pups, concentration of hydrogen, and length
of hydrogen exposure). Additionally, Sato et al [197]
reported that administering hydrogen-rich water to vita-
min C-depleted SMP30/GNL knockout mice during both
hypoxia and regeneration markedly decreased the levels of
hydroxyl and superoxide in brain slices. Li et al [198],
examined if hydrogen-rich saline reduced amyloid b (Ab)-
induced neural inflammation, as well as learning and
memory deficits in a rat model. The results showed that
intraperitoneal injections of hydrogen-rich saline, which
were administerd daily once for 2 consecutive weeks,
could improve the cognitive and memory functions in rat
models with amyloid b 1-42-induced Alzheimer’sb y
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middle cerebral artery occlusion model, administering
injections of 50% dextrose, and hydrogen gas during the
reperfusion (for 2 h) reduced brain infarction, hemorrha-
gic transformation, and improved neurological function in
rats [199].
Oral intake of hydrogen-supplemented water is an
alternative mode of hydrogen delivery. Nagata et al [200]
tested a hypothesis that drinking hydrogen water ad libi-
tum, instead of inhaling hydrogen gas, prevents cognitive
impairment by reducing oxidative stress. Their findings
demonstrated that the consumption of hydrogen water
could prevent the stress (chronic physical restraint)-
induced decline in learning and memory in a mouse
model via reduction of oxidative stress. In a 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Par-
kinson’s disease model, Fujita et al showed that drinking
hydrogen-containing water (even as low as 0.04 mM)
significantly reduced the loss of dopaminergic neuron.
Additionally, reductions in oxidative stress were demon-
strated by a significant decrease of 8-oxoguanine
(8-oxoG), a marker of DNA damage, and 4-hydroxynone-
nal (4-HNE), a marker of lipid peroxidation [201]. In a
rat Parkinson’s disease model induced by intrastriatal
injection of catecholaminergic neurotoxin 6-hydroxydo-
pamine (6-OHDA), Fu et al found that oral intake of
hydrogen water could prevent both the development and
progression of nigrostrital degeneration, and pre-and
post-treatment with hydrogen prevented dopaminergic
cell loss [202]. Therefore, they concluded that hydrogen
water was likely to retard the development and progres-
sion of Parkinson’s disease. Gu et al investigated the
efficacies of drinking hydrogen water to prevent spatial
memory decline and age-related brain alterations.
Table 3 Summary of Neuroprotective Effect of Hydrogen
Model Intervention Results Reference
MCAO 1%, 2%, 4% hydrogen during the occlusion
(85 min), or reperfusion (35 min) or
occlusion + reperfusion (120 min)
Inhalation of hydrogen markedly suppresses brain injury
by buffering the effects of oxidative stress. 2% hydrogen
is more effective than 4% and 1% hydrogen
[190]
neonatal HI 2% hydrogen (30, 60 and 120 min) or
hydrogen saturated saline (5 ml/kg
immediately and 8 h after insult)
Hydrogen treatment significantly reduces the apoptotic
cells, suppresses caspase-3 and -12 activities, reduces
MDA and Iba-1 levels, and improves the long-term
neurological and neurobehavioral functions
[194,195]
newborn pig asphyxia 2.1% H2-supplemented room air for 1 h
and additional 3 h
H2-RA ventilation significantly increases cerebrovascular
reactivity to hypercapnia after asphyxia/reventilation; no
affects on ROS-dependent cerebrovascular reactivity to
NMDA
[209]
neonatal HI
MCAO
Inhalation of 2.9% hydrogen Inhalation of 2.9% hydrogen did not decrease the
infarction volume and brain lipid peroxidation, but there
was a trend suggesting a beneficial effect on MCAO in
adult rats
[196]
hypoxia-reoxygenation of brain
slices of vitamin C-depleted
SMP30/GNL knockout mice
hydrogen-rich pure water Hydrogen-rich pure water acts as an anti-oxidant and
prevents superoxide formation
[197]
amyloid-b-induced Alzheimer’s
disease
Intraperitoneal hydrogen rich saline (5 ml/
kg daily for 2 weeks)
Hydrogen-rich saline prevents beta-induced
neuroinflammation and oxidative stress, which may
contribute to the improvement of memory dysfunction
in this rat model
[198]
MCAO Inhalation of 2.9% hydrogen during
reperfusion
Inhalation of hydrogen during 2 h reperfusion was
found to reduce brain infarction, hemorrhagic
transformation, and improve neurological function
[199]
chronic physical restraint in mice Oral intake of hydrogen supplemented
water up to 8 weeks
Hydrogen water reduces oxidative stress in the brain,
and prevents the stress-induced decline in learning and
memory caused by chronic physical restraint
[200]
MPTP induced Parkinson’s
disease model
Oral intake of hydrogen containing water
for 28 days
Drinking hydrogen-containing water significantly
reduces the loss of dopaminergic neurons accompanied
by significant reduction of oxidative stress which was
demonstrated by a significant decrease of DNA damage
and lipid peroxidation.
[201]
6-OHDA induced Parkinson’s
disease model
Oral intake of hydrogen containing water
before and after surgery
Prevent both the development and progression of the
nigrostrital degeneration and dopaminergic cell loss
[202]
Senescence-accelerated mice Oral intake of hydrogen containing water
for 30 days and 18 weeks
Prevented age-related declines in cognitive ability
increases brain serotonin levels and elevates serum
antioxidant activity at 30 days while inhibiting
neurodegeneration in the hippocampus at 18 weeks
[203]
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(SAMP8) with hydrogen water for 30 days was found to
prevent age-related declines in cognitive ability, which
were associated with increased brain serotonin levels, ele-
vated serum antioxidant activity, and inhibition of neuro-
degeneration in the hippocampus [203].
Argon
The neuroprotective effects of argon have been confirmed
in both in vivo and in vitro studies. One study led by
Ryang et al., analyzed the possible neuroprotective role of
argon post-treatment in an in vivo rat model of acute focal
cerebral ischemia [204]. They found that animals breath-
ing spontaneously 50 vol % argon 1 hr after induction of
transient middle cerebral artery occlusion for 1 hr by face
mask showed significantly reduced infarct volumes and
composite adverse outcomes. Similarly, Loetscher et al.
showed using in vitro studies that argon post-treatment
could reduce damages following oxygen-glucose depriva-
tion and traumatic brain injury [205]. Although both stu-
dies along with various other studies [206] published in
the literature have shown favorable support for Argon’s
neuroprotective characteristics, evidence is lacking with
regards to the exact mechanism and more studies are
required to clarify these mechanisms.
Conclusion
Although the protective effects of the aforementioned
gases have been extensively investigated as a therapeutic
option following various neurobiological diseases and
events, the definite efficacy and mechanisms of action of
these gases should be further validated in more well-
designed, clinical trials.
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